MicroRNAs in Cerebrospinal Fluid as Biomarkers in Brain Tumor Patients
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články, přehledy
PubMed
31216849
DOI
10.14735/amko2019181
PII: 112813
Knihovny.cz E-zdroje
- Klíčová slova
- biomarkers, brain tumors, cerebrospinal fluid, microRNAs,
- MeSH
- lidé MeSH
- mikro RNA mozkomíšní mok MeSH
- nádorové biomarkery mozkomíšní mok genetika MeSH
- nádory mozku genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- mikro RNA MeSH
- nádorové biomarkery MeSH
Backround: Although central nervous system (CNS) tumors are not the most common cancers, their incidence rate is constantly growing. Unfortunately, this group of cancers is characterized by a very poor prognosis with a very short average patient survival. Appropriate therapy depends on early and accurate diagnosis. However, this is often limited by brain tumor localization and heterogeneity. Therefore, new diagnostic approaches and biomarkers that are robust, sensitive, specific, and also without need of invasive biopsy, are still being sought. Cerebrospinal fluid (CSF) comes into direct contact with the CNS and becomes a suitable source of biological material that could reflect actual state of CNS. Suitable molecules in this regard appear to be microRNAs (miRNAs), short non-coding RNAs, that have been already detected in CSF and whose dysregulated levels are associated with various types of brain tumors. Purpose: Unfortunately, the methodical approaches used for CSF miRNA analysis have not been sufficiently standardized yet. For this reason, we summarize and evaluate methodical approaches which were previously used for miRNA analysis from CSF in order to find the most appropriate ones. Subsequently, we review studies focused on miRNA with potential to become biomarkers of CNS tumors in the future. Supported by Ministry of Health of the Czech Republic, grants No. 15-34553A and 15-33158A. All rights reserved. The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers. Submitted: 3. 1. 2019 Accepted: 3. 1. 2019.
Citace poskytuje Crossref.org